Reference |
Drug |
Design |
No Patients |
Time Follow-Up |
End Point Results |
Hausleiter J et al. [7] |
Sirolimus |
(3 arms)
BMS + placebo vs. BMS + usual-dose sirolimus vs. BMS + high-dose sirolimus |
300 |
12 months |
Positive(angiographic) |
Cernigliaro C et al. [9] |
Sirolimus |
(2 arms)
BMS + placebo vs. BMS + sirolimus |
108 |
60 months |
Positive(angiographic) |
Rodriguez AE et al. [8] |
Sirolimus |
(2 arms)
BMS + sirolimus vs. BMS |
100 |
9 months |
Positive(angiographic) |
Stojkovic S et al. [10] |
Sirolimus |
BMS + sirolimus vs. BMS |
80 |
6 months |
Positive(angiographic) |
Rodriguez AE et al. [14] |
Sirolimus |
(2 arms)
BMS + sirolimus vs. DES |
200 |
36 months |
Positive (cost-effectiveness) |
Versaci F et al. [11] |
Prednisone |
(2 arms)
BMS |
83 |
12 months |
Positive(clinical) |
Ribichini F et al. [13] |
Prednisone |
(3 arms)
BMS vs. BMS + prednisone vs. DES |
375 |
12 months |
Positive(clinical) |
BMS: Bare Metal Stents; DES: Drug Eluting Stents |
